Sagetis Biotech, a Barcelona, Spain-based a drug delivery company, has closed a $2m second funding round.
Investors include Caixa Capital Risc, and business angels from the IESE Network. Other funds came from public organizations.
Founded in 2010 as a spin off from Grupo de Ingeniería de Materiales del Instituto Químico de Sarriá (IQS), Sagetis focuses on developing develops release systems which allow the more effective administration of drugs to treat diseases of the central nervous system.
Led by Eduard Diviu Terradas, the company intends to use the funds to advance its technology, identify new compounds, and increase its staff.